+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Specialty Drug Distribution Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon

    Report

  • 133 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5669236

The trend in specialty drug distribution is shifting towards personalized and integrated healthcare solutions

The Global Specialty Drug Distribution Market is estimated to be USD 2.48 Bn in 2023 and is expected to reach USD 5.03 Bn by 2028 growing at a CAGR of 15.16%.

  • In order to effectively distribute specialized drugs used to treat complicated and unusual medical problems, a sophisticated supply chain and logistical procedures are required for specialty drug distribution. These medications frequently require specific handling, storage, and patient support services because of their high cost, sporadic availability, and distinctive delivery techniques.
  • The market for specialty drugs distribution is being driven by the rise in demand for advanced, specialized drugs to treat complex medical conditions. Healthcare professionals and patients are seeking access to these advanced medicines because these medications offer creative therapeutic options and better patient results.
  • The increased prevalence of chronic, life-threatening diseases like cancer, autoimmune diseases, and rare genetic disorders is fueling the need for specialty drugs. A strong distribution infrastructure is necessary to ensure timely and widespread access to specific drugs and biological materials because traditional treatments may sometimes be insufficient.
  • Governments worldwide understand how crucial it is to support the pharmaceutical industry R&D. Pharmaceutical companies participate in specialized drug research and production due to supportive laws, financial incentives, and financing schemes designed to accelerate the development of treatments for rare diseases and unmet medical needs. This in turn increases the need for efficient specialized pharmaceuticals delivery systems to introduce innovative treatments to the market successfully.
  • Patient assistance programs give a business opportunity for specialty drug distribution because specialty drugs can have a high cost. These initiatives, which are frequently organized by pharmaceutical firms or nonprofit groups, are designed to assist patients who are struggling financially by offering financial assistance or cost-sharing plans, boosting patient access to pharmaceuticals, and improving patient adherence to medications.
  • Due to their sensitivity to temperature and other environmental factors, specialized medications must be kept intact. The market opportunity is in developing and executing strong cold chain management systems that track and regulate temperature during transportation and storage. Drugs are delivered to patients in the best possible condition due to specialized packaging, temperature-sensitive tracking, and advanced environmental systems, decreasing wastage and raising patient safety. This creates opportunities for logistics firms to provide specialized services catered to the specific needs of the specialty medicine distribution sector.
  • However, the specialty drugs distribution industry has to deal with fluctuating drug pricing brought on by a variety of causes, such as shifting market demand, patent expirations, and adjustments to regulatory laws. These price swings may impact the profit margins of distributors and healthcare providers, making inventory management and financial planning more difficult.
  • Specialty drug reimbursement policies can be complex and restricted. For some specialty drugs, there may be restrictions on insurance coverage, government reimbursement programs, and formulary inclusion. Access to these medications is made more difficult as a result, which reduces demand and may have an adverse effect on the distribution market's future potential. Prior authorization requirements and drawn-out approval procedures can further restrict patients' access to these essential treatments.
  • The market challenges posed by a shifting regulatory environment refers to the industry-specific rules, regulations, and compliance standards that are continuously updated and changed. Companies must have a lot of resources and agility to adapt to these changes in order to stay compliant and competitive in the market.

Market Segmentations

  • The Global Specialty Drug Distribution Market is segmented based on Indications, Type, End User, and Geography.
  • By Indications, the Global Specialty Drug Distribution Market is classified into AIDS, Hemophilia, Multiple Sclerosis, oncology, and Rheumatoid Arthritis.
  • Oncology holds a larger market share. This is due to the high incidence of cancer and the wide variety of specialized oncology medications. The market for the distribution of oncology drugs is expanding as a result of the significant investments and research focus placed on cancer treatments.
  • By Type, the Global Specialty Drug Distribution Market is classified into Full Line Wholesalers and Specialty Distributors.
  • Full-line wholesalers hold a significant market share. Full line wholesalers control the majority of the pharmaceutical distribution business since they deal with a wide range of pharmaceutical items, including specialty medications.
  • By End Users, the Global Specialty Drug Distribution Market is classified into Hospitals & Clinic and Pharmacy.
  • Hospital & Clinics hold a larger market share. This is due to the high demand for specialized pharmaceuticals in hospital settings, which is fueled by complex medical conditions and critical care requirements.
  • By Geography, the Global Specialty Drug Distribution Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
  • The Americas hold a larger market share in the specialty drug distribution sector. This is due to the region's developed healthcare system, higher prevalence of chronic diseases, and easier accessibility to specialty medications, which are fueling market expansion in the Americas.

Recent Development

  • ASX23: Specialty Drugs Dominating New FDA Approvals in 2023 - May 2023
  • McKesson Signs Agreement to Acquire Rx Savings Solutions. - September 2022

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Alliance Healthcare, AmerisourceBergen Corp., Anda, Inc., Medipal Holdings, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Specialty Drug Distribution Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Specialty Drug Distribution Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Specialty Drug Distribution Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research0
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
1 Market Dynamics
1.1 Impact Analysis
1.2 Drivers
1.2.1 Increasing Demand and Significance of Drugs
1.2.2 Prevalence of Life-Threatening Disorders
1.2.3 Government Support for Drug Development
1.3 Restraints
1.3.1 Volatility Prices of the Drugs
1.3.2 Limited Reimbursement Options
1.4 Opportunities
1.4.1 Patient Assistance Programs to Help Patients Afford Their Treatments
1.4.2 Cold Chain Management for Temperature Monitoring and Sophisticated Environment System
1.5 Challenges
1.5.1 Changing Regulatory Framework
2 Market Analysis
2.1 Regulatory Scenario
2.2 Porter’s Five Forces Analysis
2.3 PESTLE Analysis
2.4 Impact of COVID-19
2.5 Ansoff Matrix Analysis
3 Market Analysis
3.1 Regulatory Scenario
3.2 Porter’s Five Forces Analysis
3.3 PESTLE Analysis
3.4 Impact of COVID-19
3.5 Ansoff Matrix Analysis
4 Global Specialty Drug Distribution Market, By Indications
4.1 Introduction
4.2 AIDS
4.3 Hemophilia
4.4 Multiple Sclerosis
4.5 Oncology
4.6 Rheumatoid Arthritis
5 Global Specialty Drug Distribution Market, By Type
5.1 Introduction
5.2 Full line Wholesalers
5.3 Specialty Distributors
6 Global Specialty Drug Distribution Market, By End Users
6.1 Introduction
6.2 Hospital & Clinic
6.3 Pharmacy
7 America’s Specialty Drug Distribution Market
7.1 Introduction
7.2 Argentina
7.3 Brazil
7.4 Canada
7.5 Chile
7.6 Colombia
7.7 Mexico
7.8 Peru
7.9 United States
7.10 Rest of Americas
8 Europe's Specialty Drug Distribution Market
8.1 Introduction
8.2 Austria
8.3 Belgium
8.4 Denmark
8.5 Finland
8.6 France
8.7 Germany
8.8 Ireland
8.9 Italy
8.10 Luxembourg
8.11 Netherlands
8.12 Norway
8.13 Poland
8.14 Russia
8.15 Spain
8.16 Sweden
8.17 Switzerland
8.18 United Kingdom
8.19 Rest of Europe
9 Middle East and Africa's Specialty Drug Distribution Market
9.1 Introduction
9.2 Egypt
9.3 Israel
9.4 Qatar
9.5 Nigeria
9.6 Saudi Arabia
9.7 South Africa
9.8 United Arab Emirates
9.9 Rest of MEA
10 APAC's Specialty Drug Distribution Market
10.1 Introduction
10.2 Australia
10.3 Bangladesh
10.4 China
10.5 India
10.6 Indonesia
10.7 Japan
10.8 Malaysia
10.9 Philippines
10.10 Singapore
10.11 South Korea
10.12 Sri Lanka
10.13 Thailand
10.14 Taiwan
10.15 Rest of Asia-Pacific
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
12 Company Profiles
12.1 Alliance Healthcare
12.1.1 Company Overview
12.1.2 Company Snapshot
12.1.3 Product Overview
12.1.4 Business Overview
12.1.5 SWOT Analysis
12.1.6 Recent Developments
12.2 AmerisourceBergen Corp.
12.2.1 Company Overview
12.2.2 Company Snapshot
12.2.3 Product Overview
12.2.4 Business Overview
12.2.5 SWOT Analysis
12.2.6 Recent Developments
12.3 Anda, Inc.
12.3.1 Company Overview
12.3.2 Company Snapshot
12.3.3 Product Overview
12.3.4 Business Overview
12.3.5 SWOT Analysis
12.3.6 Recent Developments
12.4 Avella Specialty Pharmacy
12.4.1 Company Overview
12.4.2 Company Snapshot
12.4.3 Product Overview
12.4.4 Business Overview
12.4.5 SWOT Analysis
12.4.6 Recent Developments
12.5 Cardinal Health, Inc.
12.5.1 Company Overview
12.5.2 Company Snapshot
12.5.3 Product Overview
12.5.4 Business Overview
12.5.5 SWOT Analysis
12.5.6 Recent Developments
12.6 CuraScript, Inc.
12.6.1 Company Overview
12.6.2 Company Snapshot
12.6.3 Product Overview
12.6.4 Business Overview
12.6.5 SWOT Analysis
12.6.6 Recent Developments
12.7 CVS Health Corp.
12.7.1 Company Overview
12.7.2 Company Snapshot
12.7.3 Product Overview
12.7.4 Business Overview
12.7.5 SWOT Analysis
12.7.6 Recent Developments
12.8 Diplomat Pharmacy, Inc.
12.8.1 Company Overview
12.8.2 Company Snapshot
12.8.3 Product Overview
12.8.4 Business Overview
12.8.5 SWOT Analysis
12.8.6 Recent Developments
12.9 Express Scripts Holding Co.
12.9.1 Company Overview
12.9.2 Company Snapshot
12.9.3 Product Overview
12.9.4 Business Overview
12.9.5 SWOT Analysis
12.9.6 Recent Developments
12.10 Jointown Pharmaceutical Group
12.10.1 Company Overview
12.10.2 Company Snapshot
12.10.3 Product Overview
12.10.4 Business Overview
12.10.5 SWOT Analysis
12.10.6 Recent Developments
12.11 Max Pharma
12.11.1 Company Overview
12.11.2 Company Snapshot
12.11.3 Product Overview
12.11.4 Business Overview
12.11.5 SWOT Analysis
12.11.6 Recent Developments
12.12 McKesson Corp.
12.12.1 Company Overview
12.12.2 Company Snapshot
12.12.3 Product Overview
12.12.4 Business Overview
12.12.5 SWOT Analysis
12.12.6 Recent Developments
12.13 Mediceo Paltac Holdings Co., Ltd.
12.13.1 Company Overview
12.13.2 Company Snapshot
12.13.3 Product Overview
12.13.4 Business Overview
12.13.5 SWOT Analysis
12.13.6 Recent Developments
12.14 Medipal Holdings
12.14.1 Company Overview
12.14.2 Company Snapshot
12.14.3 Product Overview
12.14.4 Business Overview
12.14.5 SWOT Analysis
12.14.6 Recent Developments
12.15 Pfizer Inc.
12.15.1 Company Overview
12.15.2 Company Snapshot
12.15.3 Product Overview
12.15.4 Business Overview
12.15.5 SWOT Analysis
12.15.6 Recent Developments
12.16 Phoenix Group
12.16.1 Company Overview
12.16.2 Company Snapshot
12.16.3 Product Overview
12.16.4 Business Overview
12.16.5 SWOT Analysis
12.16.6 Recent Developments
12.17 Shanghai Pharmaceuticals
12.17.1 Company Overview
12.17.2 Company Snapshot
12.17.3 Product Overview
12.17.4 Business Overview
12.17.5 SWOT Analysis
12.17.6 Recent Developments
12.18 Sinopharm
12.18.1 Company Overview
12.18.2 Company Snapshot
12.18.3 Product Overview
12.18.4 Business Overview
12.18.5 SWOT Analysis
12.18.6 Recent Developments
12.19 Smith Drug Co., Inc.
12.19.1 Company Overview
12.19.2 Company Snapshot
12.19.3 Product Overview
12.19.4 Business Overview
12.19.5 SWOT Analysis
12.19.6 Recent Developments
12.20 Walgreens Boots Alliance, Inc.
12.20.1 Company Overview
12.20.2 Company Snapshot
12.20.3 Product Overview
12.20.4 Business Overview
12.20.5 SWOT Analysis
12.20.6 Recent Developments
13 Appendix
13.1 Self-Assessment Form

Companies Mentioned

  • Alliance Healthcare
  • AmerisourceBergen Corp.
  • Anda, Inc.
  • Avella Specialty Pharmacy
  • Cardinal Health, Inc.
  • CuraScript, Inc.
  • CVS Health Corp.
  • Diplomat Pharmacy, Inc.
  • Express Scripts Holding Co.
  • Jointown Pharmaceutical Group
  • Max Pharma
  • McKesson Corp.
  • Mediceo Paltac Holdings Co., Ltd.
  • Medipal Holdings
  • Pfizer Inc.
  • Phoenix Group
  • Shanghai Pharmaceuticals
  • Sinopharm
  • Smith Drug Co., Inc.
  • Walgreens Boots Alliance, Inc.

Table Information